Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Lymphoma Clinical Trial

Official title:

Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00301951
• Other study ID #: CDR0000465362
• Secondary ID: UCSF-04253UCSF-2
• Status: Completed
• Phase: Phase 1
• First received: March 9, 2006
• Last updated: October 10, 2017
• Start date: September 2004
• Est. completion date: July 2009

Study information

• Verified date: October 2017
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving chemotherapy, such as fludarabine and busulfan, and antithymocyte globulin before transplant and tacrolimus and mycophenolate mofetil after transplant may stop this from happening.

PURPOSE: This clinical trial is studying how well giving low-dose fludarabine and busulfan together with anti-thymocyte globulin, followed by donor umbilical cord blood transplant works in treating patients with advanced hematologic cancer.

Description:

OBJECTIVES:

Primary

• Assess the feasibility of performing umbilical cord blood transplants in older patients or younger infirm patients with advanced hematologic malignancies using a reduced-intensity preparative regimen, as determined by > 80% engraftment rate at day 180 and a < 50% transplant-related mortality rate at day 100.

Secondary

• Describe the time to neutrophil and platelet recovery in patients treated with this regimen.

• Determine disease-specific, event-free, and overall survival rate at days 180 and 360.

• Determine the incidence, severity, and timing of acute and chronic graft-versus-host disease in patients treated with this regimen.

• Evaluate T-cell, B-cell, and natural killer cell recovery in patients treated with this regimen.

• Assess lineage-specific chimerism after transplantation and describe the contribution of each individual cord blood unit to post-transplantation hematopoiesis.

OUTLINE: This is a pilot study.

• Reduced-intensity preparative regimen: Patients receive fludarabine IV over 30 minutes on days -8 to -4, busulfan IV over 2 hours 4 times daily on days -4 and -3, and anti-thymocyte globulin IV over 6 hours on days -3 to -1.

• Allogeneic umbilical cord blood transplantation: Patients undergo allogeneic umbilical cord blood transplant on day 0. Patients receive sargramostim (GM-CSF) subcutaneously or IV beginning on day 7 and continuing until blood counts recover.

• Graft-versus-host disease (GVHD) prophylaxis: Patients receive tacrolimus IV continuously over 24 hours or orally (as tolerated) beginning on day -2 and continuing for approximately 9 months. Patients also receive oral mycophenolate mofetil twice daily on days 1-50.

After completion of study treatment, patients are followed periodically for 2 years.

PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: July 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following advanced hematologic malignancies:

• Acute myeloid leukemia (AML) meeting the following criteria:

• Considered incurable with chemotherapy

• Marrow blasts = 10% (may be achieved using standard chemotherapy regimen)

• Meets any of the following criteria:

• High-risk cytogenetics (-7, -7q, -5, -5q, t(6,9), t(9,11), complex [= 3 abnormalities], Philadelphia chromosome positive [Ph+])

• AML evolved from prior myelodysplasia

• AML secondary to prior chemotherapy

• Failed to achieve remission

• In second or subsequent remission

• Refractory relapse

• Myelodysplastic syndromes (MDS) meeting the following criteria:

• Must have high-risk features, including any of the following:

• Intermediate-2 or high risk International Prognostic Scoring System (IPSS) score

• Chronic myelomonocytic leukemia

• Marrow blasts = 20% (chemotherapy may be given to achieve target blast levels)

• No rapidly progressive disease

• Acute lymphoblastic leukemia meeting the following criteria:

• Considered incurable with chemotherapy

• Meets any of the following criteria:

• High-risk cytogenetics (Ph+, t(4,11), 11q23 abnormalities, or monosomy 7)

• Required > 1 induction course to achieve remission

• Failed to enter remission

• In second or subsequent remission

• Marrow blasts = 10% (chemotherapy may be given to achieve target blast levels)

• Chronic myelogenous leukemia (CML) meeting 1 of the following criteria:

• Chronic phase CML that failed imatinib mesylate therapy, as defined by progressive disease or failed to achieve a major cytogenetic response at 1 year after initiation of therapy

• Accelerated phase CML meeting 1 of the following criteria:

• Failed to achieve a complete cytogenetic remission at 1 year after initiation of therapy

• Failed to achieve any cytogenetic response after 6 months of therapy

• Progressive disease, as demonstrated by worsening cytogenetic response in 2 consecutive analyses separated by 4 weeks

• In blast crisis with < 10% blasts in bone marrow

• Multiple myeloma meeting the following criteria:

• Stage I-III disease

• Meets any of the following criteria:

• In relapse after autologous transplantation

• Refractory to = 2 prior conventional myeloma therapies

• Chromosome 13 abnormalities (may be enrolled at diagnosis or after initial progression)

• Lymphoma

• The following subtypes are eligible:

• Diffuse large cell

• Follicular large cell

• Mantle cell

• Peripheral T-cell

• T-natural killer (T-NK) cell

• Hodgkin's lymphoma

• Must have progressed, recurred after prior therapy, or failed to respond to primary therapy

• Relapsed disease after autologous stem cell transplantation (SCT) allowed

• Low-grade non-Hodgkin's lymphoma meeting 1 of the following criteria:

• Relapsed or refractory disease after = 2 chemotherapy-based treatment regimens

• Relapsed after autologous SCT

• Chronic lymphocytic leukemia

• Relapsed or refractory disease after = 2 chemotherapy-based treatment regimens

• Relapsed after autologous SCT

• Meets 1 of the following criteria:

• Age 55-70 years

• Under age 55 and deemed ineligible for conventional high-dose chemotherapy, as indicated by any of the following:

• Poor cardiac function (i.e., LVEF < 40%)

• Poor pulmonary function (i.e., DLCO < 50%)

• Hepatic dysfunction

• Prior myeloablative therapy

• Not eligible for autologous SCT or conventional therapy

• Umbilical cord blood donor available

• Matched at = 4 of 6 HLA antigens (A, B, and DR)

• Has 1-3 units of umbilical cord blood available

• Must not have an HLA-identical or 1 antigen mismatched related donor or potential HLA-matched unrelated donor readily available NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Creatinine clearance > 40 mL/min

• Creatinine < 2.0 mg/dL

• AST and alkaline phosphatase < 3 times upper limit of normal (ULN)

• Bilirubin < 2.0 mg/dL

• Hepatitis C or active hepatitis B virus (HBV) allowed if = grade 2 fibrosis and/or inflammation by liver biopsy

• Patients with history of HBV infection should be tested for hepatitis B epsilon (HBe) antigen, anti-HBe, and HBV DNA (quantitative)

• Patients with active HBV viral replication should receive antiviral therapy

• Ejection fraction > 30%

• DLCO = 40%

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No active infection requiring ongoing antibiotic treatment

• HIV negative

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Related Conditions & MeSH terms

• Leukemia
• Lymphoma
• Multiple Myeloma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Syndromes
• Neoplasms, Plasma Cell
• Plasmacytoma
• Preleukemia
• Syndrome

Intervention

Biological:
• anti-thymocyte globulin

• sargramostim

Drug:
• busulfan

• fludarabine phosphate

• mycophenolate mofetil

• tacrolimus

Procedure:
• umbilical cord blood transplantation

Locations

Country	Name	City	State
United States	UCSF Comprehensive Cancer Center	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Feasibility of donor cord blood transplant	as determined by > 80% engraftment rate at day 180 and a < 50% transplant-related mortality rate at day 100	up to 36 months post transplant